Southern Illinois University School of Medicine, Springfield, Illinois, USA.
Marshfield Clinic Research Institute, Research Computing and Analytics, Marshfield, Wisconsin, USA.
Clin Med Res. 2024 Mar;22(1):1-5. doi: 10.3121/cmr.2024.1848.
Most recent clinical reports from the American Academy of Pediatrics (AAP) concluded current evidence does not support routine universal administration of probiotics to preterm infants, particularly those with birth weight <1000 grams. Despite this, the use of probiotics is increasing in US neonatal intensive care units (NICU). Collaborating with the Perinatal Neonatal Medicine of AAP, we conducted a national survey to obtain neonatologist opinion on probiotics use. Survey questionnaires were sent to 3000 neonatologists via email. Of 3000 potential respondents, 249 (8.3 %) completed the survey. Seventy-five (30%) neonatologists working in 23 different NICUs reported using probiotics in their practice, while 168 (70%) neonatologists working in 54 different NICUs reported not using probiotics. Of those not currently use probiotics, 49% indicated they would consider using probiotics in the future vs. 12% indicating they would not use probiotics. The most common indication for probiotics use was average gestational age < 32 weeks and mean birth weight < 1500 grams. Probiotics were discontinued at mean gestational age of 35 weeks. Respondents who prescribe probiotics were more likely to work in a setting without fellowship or residency training (48% vs 20%). Probiotics users were more often from the West (29 % vs 7%) and less often from Northeast (5% vs 34%) compared to non-users. The proportion of those using probiotics did not significantly differ by NICU size, NICU level, or years working in a NICU. Similac Tri-Blend, Evivo, and Culturelle were the top three probiotics used in the respondent's NICU. Though a majority of respondents are not currently using probiotics in their NICU, a large number of nonusers are interested in using probiotics in the future. Differences continue to exist in the brand of probiotics used in US NICUs.
最近美国儿科学会（AAP）的临床报告得出结论，目前的证据并不支持常规普遍给予早产儿益生菌，特别是出生体重<1000 克的早产儿。尽管如此，益生菌在美国新生儿重症监护病房（NICU）的使用仍在增加。与 AAP 的围产期新生儿医学合作，我们进行了一项全国性调查，以了解新生儿科医生对益生菌使用的看法。通过电子邮件向 3000 名新生儿科医生发送了调查问卷。在 3000 名潜在受访者中，有 249 名（8.3%）完成了调查。在 23 家不同的 NICU 工作的 75 名（30%）新生儿科医生报告在他们的实践中使用了益生菌，而在 54 家不同的 NICU 工作的 168 名（70%）新生儿科医生报告没有使用益生菌。在那些目前不使用益生菌的人中，49%表示他们将来会考虑使用益生菌，而 12%表示他们不会使用益生菌。使用益生菌最常见的指征是平均胎龄<32 周和平均出生体重<1500 克。益生菌在平均胎龄 35 周时停止使用。开益生菌处方的受访者更有可能在没有奖学金或住院医师培训的环境中工作（48%比 20%）。益生菌使用者更多来自西部（29%比 7%），而较少来自东北部（5%比 34%）。益生菌使用者和非使用者的 NICU 规模、NICU 级别或在 NICU 工作的年限之间没有显著差异。Similac Tri-Blend、Evivo 和 Culturelle 是受访者 NICU 中使用最多的前三种益生菌。尽管大多数受访者目前不在他们的 NICU 使用益生菌，但许多非使用者有兴趣在未来使用益生菌。美国 NICU 中使用的益生菌品牌仍存在差异。
